Kymera Therapeutics (KYMR) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 near flat as traders shift out of risky AI bets
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.67), $0.03 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $16.51 million versus the consensus estimate of $13.93 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AIR Global sets first-ever dividend, $100M buyback amid business, cash strength
- Caterpillar shares drop on analyst downgrades
- Marsh shares rise 2% after beating third quarter estimates on strong revenue growt
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
